Next Article in Journal
Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease
Next Article in Special Issue
Therapeutic Target Discovery Using High-Throughput Genetic Screens in Acute Myeloid Leukemia
Previous Article in Journal
Chemical Modulation of Mitochondria–Endoplasmic Reticulum Contact Sites
Previous Article in Special Issue
Immunotherapy in Myeloproliferative Diseases

EZH2 in Myeloid Malignancies

Klinik für Innere Medizin II, Universitätsklinikum Jena, 07743 Jena, Germany
School of Medicine, University of Southampton, Southampton SO17 1BJ, UK
Wessex Regional Genetics Laboratory, Salisbury NHS Foundation Trust, Salisbury SP2 8BJ, UK
Author to whom correspondence should be addressed.
Cells 2020, 9(7), 1639;
Received: 12 June 2020 / Revised: 1 July 2020 / Accepted: 2 July 2020 / Published: 8 July 2020
(This article belongs to the Special Issue Pathophysiology and Molecular Targets in Myeloid Neoplasia)
Our understanding of the significance of epigenetic dysregulation in the pathogenesis of myeloid malignancies has greatly advanced in the past decade. Enhancer of Zeste Homolog 2 (EZH2) is the catalytic core component of the Polycomb Repressive Complex 2 (PRC2), which is responsible for gene silencing through trimethylation of H3K27. EZH2 dysregulation is highly tumorigenic and has been observed in various cancers, with EZH2 acting as an oncogene or a tumor-suppressor depending on cellular context. While loss-of-function mutations of EZH2 frequently affect patients with myelodysplastic/myeloproliferative neoplasms, myelodysplastic syndrome and myelofibrosis, cases of chronic myeloid leukemia (CML) seem to be largely characterized by EZH2 overexpression. A variety of other factors frequently aberrant in myeloid leukemia can affect PRC2 function and disease pathogenesis, including Additional Sex Combs Like 1 (ASXL1) and splicing gene mutations. As the genetic background of myeloid malignancies is largely heterogeneous, it is not surprising that EZH2 mutations act in conjunction with other aberrations. Since EZH2 mutations are considered to be early events in disease pathogenesis, they are of therapeutic interest to researchers, though targeting of EZH2 loss-of-function does present unique challenges. Preliminary research indicates that combined tyrosine kinase inhibitor (TKI) and EZH2 inhibitor therapy may provide a strategy to eliminate the residual disease burden in CML to allow patients to remain in treatment-free remission. View Full-Text
Keywords: EZH2; PRC2; ASXL1; myeloid malignancies; MDS; MPN; CML; mutations EZH2; PRC2; ASXL1; myeloid malignancies; MDS; MPN; CML; mutations
Show Figures

Figure 1

MDPI and ACS Style

Rinke, J.; Chase, A.; Cross, N.C.P.; Hochhaus, A.; Ernst, T. EZH2 in Myeloid Malignancies. Cells 2020, 9, 1639.

AMA Style

Rinke J, Chase A, Cross NCP, Hochhaus A, Ernst T. EZH2 in Myeloid Malignancies. Cells. 2020; 9(7):1639.

Chicago/Turabian Style

Rinke, Jenny, Andrew Chase, Nicholas C.P. Cross, Andreas Hochhaus, and Thomas Ernst. 2020. "EZH2 in Myeloid Malignancies" Cells 9, no. 7: 1639.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop